EP Patent

EP3763211A1 — Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof

Assigned to Boehringer Ingelheim Animal Health USA Inc · Expires 2021-01-13 · 5y expired

What this patent protects

This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutically acceptable additive or excipient. This…

USPTO Abstract

This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutically acceptable additive or excipient. This invention also provides new isoxazoline active agents with long-lasting efficacy against ectoparasites. The invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the novel isoxazoline compounds and long-acting injectable compositions of the invention to the animal in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3763211A1
Jurisdiction
EP
Classification
Expires
2021-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Animal Health USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.